Study of the effect of Baricitinib on the Course of COVID-19
Alina Yuryevna Maslova, Alla Aslanbekovna Tskaeva, Zuleykha Abdulkerimkizi Ashurova, AlinaTemrukovna Abazova, Magomed Muradovich Ismailov, Maryam Muradovna Ismailova, Igor Spartakovich Baklanov, Artem Evgenevich Mishvelov, Sergey Nikolaevich Povetkin, Olga Aleksandrovna Baklanova
Journal of Pharmaceutical Research International · pp. 204–213 · Published 6 Jul 2021
10.9734/jpri/2021/v33i35A31890Abstract
The aim of the study was to determine the effect of the inhibitor of janus kinase – baricitinib ("Olumiant") on the course of COVID-19. This drug baricitinib is able to suppress the systemic inflammatory response, which is one of the common causes of death in COVID-19, is an urgent problem of the study. The study was carried out in the Regional Specialized Budget Infectious Diseases Hospital of Stavropol (Russian Federation, Stavropol Region). In a multivariate analysis, it was shown that the use of baricitinib was associated with a decrease in the frequency of the primary endpoint of death/need for invasive lung ventilation. The use of baricitinib was quite safe, but in some patients there was an increase in the level of transaminases. No cases of hypercoagulation have been reported while taking baricitinib. It was found that patients with a normal BMI are more sensitive to therapy than those who are overweight.75% of patients in the first group had a temperature above 38.0oC. However, against the background of taking the standard treatment regimen and baricitinib, it was noted that the temperature stabilized during the day and did not rise again. Against the background of taking baricitinib, the elimination of the phenomena of respiratory failure and the refusal of an oxygen mask occurred 3.1 times more often than without baricitinib. The authors concluded that the use of baricitinib can be considered as an additional therapy for moderate forms of pneumonia in patients over 65 years or in patients with concomitant chronic diseases in order to suppress the reactions of systemic inflammation and the development of serious respiratory and other system lesions caused by COVID-19.
Cited by 25
Elmira Mugudinovna Musinova, Patimat Abdulayevna Omarova, Kamilla Gadzhimuradovna Aliyeva · Journal of Advanced Pharmacy Education and Research · 2023
Milana Magomedovna Dadaeva, Violetta Viktorovna Zhuravleva, Galina Vladimirovna Osipchuk · Entomology and Applied Science Letters · 2023
Cristina Mennitti, Gabriele Farina, Antonio Imperatore · International Journal of Veterinary Research and Allied Science · 2023
Natalia Georgievna Salbieva, Aida Amurkhanovna Cheldieva, Emma Gubeevna Plieva · Journal of Biochemical Technology · 2022
Tamila Akhmedovna Umarkhadzhieva, Evgenia-Mihriban Tahsinovna Lotareva, Vadim Gennadevich Gulyan · Pharmacophore · 2023
Alina Yurievna Maslova, Artem Evgenievich Mishvelov, Khapisat Nasrulaevna Nasrulaeva · Pharmacophore · 2023
Derma Dupuis, Kasinda Fritz, Emeka Ike · Cureus · 2022
Olesya Arkadyevna Ponomareva, Ibragim Magomedovich Kasumov, Adam Ruslanovich Maisigov · Journal of Medical Sciences and Interdisciplinary Research · 2023
Madina Ramazanovna Gazieva, Anastasiya Romanovna Guteneva, Maria Vladimirovna Korol · Archives of Pharmacy Practice · 2023
Umidat Shamilevna Dzhabrailova, Vagab Malikovich Vagabov, Zumrud Nasirovna Akhaeva · Pharmacophore · 2022
Showing 20 of 25 known citations — external sources report more than can currently be individually listed.
Related research
- COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
- Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
- Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
- Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review — shares topic coverage
- Addressing the Challenges of Containing Covid-19 Spread in a Rural, Poor Area in India: A Case Study — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
25
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.